Key result
Bivalirudin links to ~9-point fewer reoperations for insertion-site bleeds vs heparin in Impella 5.5.
Why the study?
To evaluate whether an institutional shift from anticoagulation with heparin to bivalirudin in Impella 5.5 patients altered bleeding or thrombotic rates, transfusion dependency, or device biocompatibility.
Does systemic anticoagulation with bivalirudin improve device biocompatibility and reduce hematologic adverse events compared to heparin in adult patients supported by Impella 5.5?
Cohort (n=168)
No
Does systemic anticoagulation with bivalirudin improve device biocompatibility and reduce hematologic adverse events compared to heparin in adult patients supported by Impella 5.5?
An institutional shift to primary bivalirudin anticoagulation in Impella 5.5 patients improved device biocompatibility, increased therapeutic time in range, and reduced insertion site bleeding compared to traditional heparin.
Answers are grounded in this paper and cite their sources.
Bivalirudin may reduce bleeding complications with Impella 5.5; hypothesis-generating and should not yet change practice pending randomized data.
Objective: To evaluate whether an institutional shift from anticoagulation with heparin to bivalirudin in Impella 5.5 patients altered bleeding or thrombotic rates, transfusion dependency, or device biocompatibility. Methods: All patients supported by an Impella 5.5 between August 2022 and December 2024 were reviewed retrospectively. Heparin was used before December 2023, at which point the switch was made to bivalirudin. Groups were defined by anticoagulant initiated by postimplantation day 2, and patients with crossover or anticoagulation pauses for >2 days were excluded from the laboratory analyses. Baseline characteristics, anticoagulation details, complications, and clinical outcomes were compared between the heparin and bivalirudin groups. Biocompatibility was assessed via laboratory values recorded over the first 14 days of Impella support or until device explantation in patients supported for <14 days. Conclusions: Systemic anticoagulation with bivalirudin in Impella 5.5 patients is associated with clinically meaningful improvements in postoperative thrombocytopenia and biocompatibility, with easier management, fewer insertion site bleeds, and more time within the target anticoagulation range.
No takes yet. Share an insight, caveat, or question.
Asher et al. (2026) conducted a cohort in Cardiogenic shock requiring Impella 5.5 support (n=168). Bivalirudin vs. Heparin (systemic drip + heparinized purge) was evaluated on Device biocompatibility assessed via laboratory values (platelet and lactate dehydrogenase recovery trends) over the first 14 days (Faster platelet and LDH recovery, p=<0.05). Bivalirudin in Impella 5.5 patients significantly improved platelet and LDH recovery (p<0.05) and reduced insertion site bleeds requiring reoperation (1% vs 10%, p=0.015) compared to heparin.
Synapse has enriched 10 related papers. Consider them for comparative context: